Pharmacolog forms an international consortium for Eurostars application

Pharmacolog has, together with a consortium consisting of the University of Lille, University Hospital in Geneva and Munkplast AB, submitted a Eurostar application for a project to develop solutions for adaptive medication with intravenous drugs.

Pharmacolog has, in collaboration with GRITA, the University of Lille, France, the University Hospital in Geneva and Munkplast AB in Uppsala submitted a Eurostar application accepted for further assessment within the Eureka / Eurostars organization.

The project; Intravenous Dose Rate Adjustment (IDRA) refers to the development of methods and systems for adaptive treatment with intravenous drugs and is scheduled to last over three years with a total budget of approximately 15 million SEK. A granted Eurostars application implies a financial contribution of up to 50% of the total project budget.

Eurostars is a cooperation program between EUREKA and the European Commission with joint funding from 36 participating countries, partner countries and the EU through the Horizon 2020 program. Eurostar’s budget over the period 2014-2020 is a total of EUR 1.14 billion. Eurostars supports international innovative cooperation projects led by small and medium-sized development companies.

Research Director Hans Dahlin comments, “I am extremely pleased that we have managed to gather two world-leading medical institutions and a Swedish company that are experts in the production of plastic products with the aid of robot automation. An approval of the project will significantly accelerate our efforts to develop solutions that enable real-time adjustment of the drug dose during ongoing treatment with intravenous drugs. The project is in line with our vision as well as the EU-focused medical research projects in the area of Personlized Medicine

Pharmacolog signs agreement with B. Braun S.A.

Pharmacolog has entered into an agreement with B. Braun Medical S.A Spain concerning exclusive distribution of DrugLog® on the Spanish market. The agreement also considers the future integration of DrugLog® with one of the company’s software Oncology technologies.

Braun Medical S.A. Spain is a company within the B. Braun Group engaged, among other activities, in the product development in the field of Injectable Drug Delivery. The area includes developing new solutions for managing the entire process of chemotherapy with cytotoxic drugs, from prescription to patient infusion. The agreement signed between Pharmacolog and B. Braun Medical Spain means that B. Braun acts as an exclusive distrib...

Pharmacolog kallar till bolagsstämma

Aktieägarna i Pharmacolog i Uppsala AB (publ), 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.

Anmälan m.m.

Aktieägare som önskar delta vid årsstämman skall:

–    dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och

–    dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till

Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (ell...

Continued negotiations with international MedTech Group

In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.

The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quar...

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...